Back to compounds

COMPOUND PROFILE / COMBINATIONS

Ipamorelin + CJC-1295 DAC.

Research draft

This entry combines ipamorelin with CJC-1295 DAC.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Identity and evidence review notes

Component references are background only. No directly matched controlled combination result was established in this pass.

Overview

This entry combines ipamorelin with CJC-1295 DAC.

CLASSIFICATIONCombinations
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCombination

Mechanism

It pairs ghrelin-receptor activity with prolonged GHRH signalling.

Human research

Component hormone studies do not establish exact-combination recovery, muscle or longevity benefit.

Preclinical & other research

Separate pharmacology provides a rationale, not proven synergy.

Safety & unknowns

Prolonged GH-axis effects, glucose responses and long-term combined safety are uncertain.

Regulatory status

No exact-combination approval was established; keep separate from the No-DAC combination.

Reported use & evidence

Research profile draft

The supplied Ipamorelin + CJC-1295 DAC profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Explore more compounds